172 related articles for article (PubMed ID: 16457875)
1. Epigenetic regulation of maspin expression in human ovarian carcinoma cells.
Rose SL; Fitzgerald MP; White NO; Hitchler MJ; Futscher BW; De Geest K; Domann FE
Gynecol Oncol; 2006 Aug; 102(2):319-24. PubMed ID: 16457875
[TBL] [Abstract][Full Text] [Related]
2. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells.
Akiyama Y; Maesawa C; Ogasawara S; Terashima M; Masuda T
Am J Pathol; 2003 Nov; 163(5):1911-9. PubMed ID: 14578190
[TBL] [Abstract][Full Text] [Related]
3. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression.
Kim S; Han J; Kim J; Park C
Cancer Res; 2004 Oct; 64(19):6900-5. PubMed ID: 15466179
[TBL] [Abstract][Full Text] [Related]
4. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of maspin expression in the human placenta.
Dokras A; Coffin J; Field L; Frakes A; Lee H; Madan A; Nelson T; Ryu GY; Yoon JG; Madan A
Mol Hum Reprod; 2006 Oct; 12(10):611-7. PubMed ID: 16936308
[TBL] [Abstract][Full Text] [Related]
7. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
8. Role for DNA methylation in the control of cell type specific maspin expression.
Futscher BW; Oshiro MM; Wozniak RJ; Holtan N; Hanigan CL; Duan H; Domann FE
Nat Genet; 2002 Jun; 31(2):175-9. PubMed ID: 12021783
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.
O'Donnell JD; Linger RJ; Kruk PA
Gynecol Oncol; 2010 Feb; 116(2):262-8. PubMed ID: 19906413
[TBL] [Abstract][Full Text] [Related]
10. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.
Ogasawara S; Maesawa C; Yamamoto M; Akiyama Y; Wada K; Fujisawa K; Higuchi T; Tomisawa Y; Sato N; Endo S; Saito K; Masuda T
Oncogene; 2004 Feb; 23(5):1117-24. PubMed ID: 14743202
[TBL] [Abstract][Full Text] [Related]
11. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation.
Yatabe Y; Mitsudomi T; Takahashi T
Oncogene; 2004 May; 23(23):4041-9. PubMed ID: 15048080
[TBL] [Abstract][Full Text] [Related]
12. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
14. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
15. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
16. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
[TBL] [Abstract][Full Text] [Related]
17. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Kang S; Dong SM; Park NH
Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
[TBL] [Abstract][Full Text] [Related]
18. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
20. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality.
Ito R; Nakayama H; Yoshida K; Oda N; Yasui W
Oncol Rep; 2004 Nov; 12(5):985-90. PubMed ID: 15492782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]